A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Study ID
- NCT07680907
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.
Key Dates
- First listed
- Jul 2, 2026
- Start date
- Jul 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Aug 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 250 participants (estimated)
Arms
- Arm: Unresectable Epidermal Growth Factor Receptor Mutated (EGFRm) NSCLCParticipants with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC), unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation will be included in this cohort. The existing secondary data from electronic health records (EHR) of these participants from approximately five selected Portuguese healthcare sites will be processed. Each participant will be followed up from index date (date on which participant is included in study) up to 31 March 2026 or at censoring, No intervention will be provided as a part of this study.
Primary Outcome Measure
Sociodemographic Characteristics: Age [ Time Frame: Baseline ]
Central Contacts
- Study Contact844-434-4210
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.Recruiting · University of Colorado, Denver · Aurora, Colorado
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Lebanon, New Hampshire
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Lebanon, New Hampshire